Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

199.22 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices ↗

January 14, 2023

Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...

Via Talk Markets

Where Ascendis Pharma Stands With Analysts ↗

November 29, 2022

Via Benzinga

What 9 Analyst Ratings Have To Say About Ascendis Pharma ↗

November 29, 2022

Via Benzinga

Analyst Ratings for Ascendis Pharma ↗

November 29, 2022

Via Benzinga

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Ascendis Pharma's Program Hits Primary Goal In Children With Short-Limbed Dwarfism ↗

November 14, 2022

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 14, 2022

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Via Benzinga

Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗

November 14, 2022

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Analyst Ratings for Ascendis Pharma ↗

November 07, 2022

Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter:

Via Benzinga

6 Analysts Have This to Say About Ascendis Pharma ↗

October 20, 2022

Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter:

Via Benzinga

Expert Ratings for Ascendis Pharma ↗

September 22, 2022

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 14, 2022

Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗

October 20, 2022

Upgrades

Via Benzinga

Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism ↗

August 31, 2022

Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid...

Via Benzinga

Expert Ratings for Ascendis Pharma ↗

August 30, 2022

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter:

Via Benzinga

What 14 Analyst Ratings Have To Say About Ascendis Pharma ↗

May 12, 2022

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:

Via Benzinga

Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know ↗

August 11, 2022

Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the...

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge ↗

May 12, 2022

Ascendis Pharma sells a treatment for children with insufficient growth hormone.

Via Investor's Business Daily

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗

March 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data ↗

March 15, 2022

Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 14, 2022

Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

March 14, 2022

Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading.

Via Benzinga

Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints ↗

March 14, 2022

Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in...

Via Benzinga

7 Biotech Stocks With Key Catalysts in March ↗

March 09, 2022

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.

Via InvestorPlace

Expert Ratings For Ascendis Pharma ↗

March 07, 2022

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

Earnings Scheduled For March 2, 2022 ↗

March 02, 2022

Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.